100 mg kapsül için Novartis 20 USD isterken Güney Kore`nin maximum fiyatı 15 USD civarı....
Novartis May Withhold Glivec in South Korea Because of Pricing
By Kristin Jensen
Basel, Switzerland, Aug. 5 (Bloomberg) -- Novartis AG may withhold the leukemia treatment Glivec from patients in South Korea because of a dispute over pricing for the product, the Financial Times reported, citing industry officials.
Europe`s third-biggest drugmaker set a price based on the average cost in seven countries, the FT said. It`s asking 24,050 won ($20) for a 100-milligram capsule, compared with the 17,862 won-limit set by South Korea, the newspaper said.
``We are very disappointed that the ministry of health has not yet reached a decision on the reimbursement price of Glivec in Korea, meaning many patients continue to be denied access,`` said Frank Bobe, director of Novartis in South Korea, according to the newspaper.
Novartis`s dispute is part of a larger battle between the South Korean government and pharmaceutical companies, the FT said. The country is struggling to cut costs as its health-insurance fund runs at a deficit, the paper said.